Human papillomavirus type 11 (HPV-11)

Human papillomavirus type 11 is a member of the Papillomaviridae family and is classified as a low-risk human papillomavirus. It is a small, non-enveloped double-stranded DNA virus that infects mucosal epithelium. Transmission occurs primarily through sexual contact. Infection with HPV type 11 can cause benign conditions such as genital warts (condyloma acuminata) and recurrent respiratory papillomatosis but rarely leads to cancer[2][3][5]. The major structural protein L1 forms virus-like particles used in prophylactic vaccines like Gardasil, which induce protective immunity against infection by stimulating antibody production without causing disease[1][4]. While not itself considered a therapeutic target like an enzyme or receptor, its proteins are used as antigens for immunization purposes. Note: HPV type 11 refers to an entire viral species rather than a single molecular target such as an enzyme or receptor. Therefore, it does not fit standard definitions for "therapeutic targets" typically used in drug discovery contexts—this makes "is_target" false and "is_incorrect" true for this context. The relevant molecular target for drugs/vaccines would be more specifically described as "Human papillomavirus type 11 L1 capsid protein antigen"[4].

Other names

HPV 11Human papillomavirus 11

For vaccines containing the L1 protein: Induces an immune response by presenting virus-like particles that mimic the native viral capsid, leading to production of neutralizing antibodies against HPV type 11.